Nasdaq Stockholm AB: The observation status for Immune Pharmaceuticals Inc. is updated (330/17)

Today, on November 13, 2017, Immune Pharmaceuticals Inc. (the "Company")
published a press release with information that the Company provides a
compliance plan to satisfy the EU Market Abuse Regulation as well as the Nasdaq
First North Nordic Rulebook, and that Nasdaq Stockholm AB (the "Exchange") has
initiated a process for referral of the matter concerning non-compliance to the
Disciplinary Committee of the Exchange for a decision on appropriate sanctions. 

The current rules of Nasdaq First North state that a listed company can be
given observation status if any circumstance exists that results in substantial
uncertainty regarding the issuer or the pricing of its financial instruments
traded on Nasdaq First North. 

With reference to that the Exchange has concluded that the Company does not
fulfil the applicable admission requirements as set out in First North Nordic
Rulebook and that the Exchange has initiated a process for referral of the
matter to the Disciplinary Committee, the Exchange has decided to update its
decision that the shares in Immune Pharmaceuticals Inc. (IMNP, ISIN code
US45254C2008, order book ID 032838) shall be given observation status. 

For further information concerning this exchange notice please contact Caroline
Sjölund or Karin Ydén, telephone + 46 8 405 60 00.